Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

ASCT may cure follicular lymphoma for some rituximab-naive patients

Key clinical point: Autologous stem cell transplantation (ASCT) can be curative in patients with follicular lymphoma who experience early failure of first-line therapy but have a response to rescue therapy.

Major finding: Relative to patients without early failure of first-line therapy, patients with early failure of first-line therapy undergoing ASCT less than 1 year later did not differ significantly in 5-year progression-free survival (66% vs. 48%, respectively; P = .44).

Study details: A multicenter retrospective cohort study of 134 patients with nontransformed follicular lymphoma who underwent ASCT during second response and did not receive rituximab.

Disclosures: The study was funded by the Foundation Research Institute at the Hospital Universitario 12 de Octubre. The researchers reported having no relevant conflicts of interest.

Citation:

Jiménez-Ubieto A et al. Hematol Oncol Stem Cell Ther. 2019 Jul 9. doi: 10.1016/j.hemonc.2019.06.001.